Trial Profile

A study of the epigenetic profiling and response to Certolizumab pegol in patients with moderate to severe RA.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Certolizumab pegol (Primary)
Indications Rheumatoid arthritis
Focus Pharmacogenomic; Therapeutic Use
Sponsors UCB

Most Recent Events

04 Jul 2013 Accrual to date is 2% according to United Kingdom Clinical Research Network.
22 Jun 2013 Planned end eate changed from 1 Sep 2013 to 1 Sep 2017 as reported by United Kingdom Clinical Research Network record.
21 Mar 2013 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com